Sponsored Links

Lung patients benefit from nutrition advice

Wed Apr 8, 2009 3:35pm EDT
 
[-] Text [+]

NEW YORK (Reuters Health) - People with chronic lung conditions tend to be underweight or malnourished, but dietary counseling can help them gain some weight and function better, new research shows.

For their study, Dr. C. Elizabeth Weekes, from St. Thomas' Hospital, London, and colleagues recruited 59 people with chronic obstructive pulmonary disease or COPD, an umbrella term for lung conditions such as emphysema or chronic bronchitis.

The participants were assigned on a random basis to receive dietary counseling and advice on food fortification or to receive a dietary advice leaflet only. The counseling was ongoing for six months, and the subjects were followed for another six months.

Daily intake of calories and protein was significantly greater in the intervention group than in the comparison group, Weekes' team reports in the medical journal Thorax.

The subjects who were counseled about nutrition gained about 2 kilograms on average in the first 6 months and maintained that gain, while the other group steadily lost about 3 kilograms over the 12 month study.

Furthermore, functional abilities and symptoms such as breathlessness improved among the counseled patients, and many of the beneficial changes persisted during the follow-up period.

By contrast, the dietary intervention appeared to have no impact on respiratory function or on muscle strength, the researchers note.

They call for further studies to identify which COPD patients are mostly likely to benefit from dietary counseling and advice on food fortification.

SOURCE: Thorax, April 2009.

 
Photo

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
A customer shops for medicine at a Portland, Oregon drugstore July 31, 2005. REUTERS/Richard Clement RC/YH
Blame game slows growth of personalized medicine

Expectation has been building for a decade that an era of personalized medicine will transform the global drugs business, but the reality is a slow start and an angry blame game between scientists, marketers and regulators.  Full Article